The study result suggested that INC42 has reduced spleen size in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), when compared with best available therapy, administered at doses and schedules determined by the investigator.
Earlier, Novartis has got license for INC424 from Incyte to develop and commercialize the product outside US.
Novartis Oncology president Herve Hoppenot said they are pleased to reach this important milestone in their collaboration to develop INC424, a compound representing potential progress for patients with myelofibrosis.